# GLP-1 Receptor Agonist Clinical Evidence: Mazdutide vs Tirzepatide > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/dual-gip-glp-1-receptor-agonists-tirzepatide-vs-mazdutide/ > **Published:** 2026-06-10T12:12:55-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:05:08-04:00 > **Clinical Summary:** Explore dual GIP GLP-1 receptor agonists like tirzepatide and mazdutide, focusing on clinical evidence and treatment implications for type 2 diabetes and obesity. --- GLP-1 Clinical Relevance  #50Moderate Clinical Relevance  Relevant context for GLP-1 prescribers; interpret with care. ⚕ GLP-1 News  |  CED Clinic Clinical CommentaryComparative AnalysisType 2 DiabetesTirzepatideEndocrinologyAdults with Metabolic DiseaseWeight Loss and Glycemic ControlDual GLP-1 GIP Receptor AgonismMazdutideInvestigational AgentsFDA-Approved MedicationsTreatment Selection Guidelines Why This Matters Tirzepatide’s dual GIP/GLP-1 receptor agonism produces superior glycemic control and weight loss compared to GLP-1 monotherapy in [clinical trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/), making it a higher-efficacy option for patients with inadequate response to semaglutide or liraglutide. As mazdutide completes development, family medicine clinicians will need to understand how its pharmacologic profile and emerging efficacy data compare to tirzepatide to optimize treatment selection in the expanding dual-agonist landscape. Current prescribing decisions for tirzepatide should be informed by its cardiovascular benefits, injection burden, and cost considerations relative to established GLP-1 agents in your patient population. Clinical Summary Mazdutide and tirzepatide are both dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonists under clinical investigation for metabolic diseases. Tirzepatide has achieved [FDA approval](https://cedclinic.com/medicare-cannabis-reimbursement-policy-fda-approval/) for both type 2 diabetes mellitus and chronic [weight management](https://cedclinic.com/cannabis-metabolism-weight-management-science/), with established dosing regimens and real-world efficacy data. Mazdutide remains investigational and has not yet received regulatory approval. Both agents function through the same dual GIP/GLP-1 mechanism, which distinguishes them from monoagonists and represents the newer generation of incretin-based therapies. The comparative positioning of these agents requires understanding their respective pharmacokinetic profiles, clinical trial outcomes, and practical prescribing considerations. Clinical trial data demonstrates that tirzepatide achieves glycemic and weight loss outcomes superior to GLP-1 monoagonists across multiple studies. In the SURPASS trials for type 2 diabetes, tirzepatide at the 15 mg dose produced mean HbA1c reductions ranging from 2.0 to 2.5 percentage points and weight loss between 7 to 13 kg depending on baseline characteristics and comparator. For obesity without diabetes, the ZEPBOUND trial showed mean weight loss of approximately 21.4% of baseline body weight at the 15 mg maintenance dose. Mazdutide, as an investigational compound, has undergone early and mid-phase clinical evaluation but does not yet have the breadth of efficacy and safety data available in the published literature that characterizes tirzepatide’s clinical profile. For prescribers, tirzepatide offers a GIP/GLP-1 agonist option with established efficacy benchmarks, known tolerability patterns, and defined regulatory pathways for both diabetes and obesity indications. The drug is available through multiple delivery systems and has predictable titration protocols. Mazdutide’s clinical position remains preliminary pending completion of later-phase trials and potential FDA submission. Until mazdutide achieves regulatory approval and comparative effectiveness data becomes available, tirzepatide represents the only approved dual GIP/GLP Clinical Takeaway Clinical Takeaway Tirzepatide is currently the only FDA-approved dual GLP-1/GIP receptor agonist available for clinical use in type 2 diabetes and obesity, while mazdutide remains investigational and not yet available for patient treatment. Tirzepatide demonstrates superior weight loss and glycemic control compared to GLP-1 monotherapy agents like semaglutide, making it a valuable option for patients with inadequate response to single-agent therapy. The choice between tirzepatide and other agents should be individualized based on patient comorbidities, treatment goals, tolerability concerns, and access considerations in your practice setting. When counseling patients about tirzepatide, clearly communicate that weekly dosing and the dual mechanism offer advantages over daily GLP-1 medications, but gastrointestinal [side effects](https://cedclinic.com/cannabis-intoxication-memory-disruption/) and cost barriers remain important practical considerations to address upfront. Dr. Caplan’s Take “Tirzepatide has established safety and efficacy data from robust [clinical trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/), which gives us confidence in dosing and patient selection today, whereas mazdutide remains investigational and we simply don’t have the long-term outcome data yet. The key clinical implication here is that when counseling patients about GLP-1 receptor agonists, we can speak to tirzepatide’s proven cardiovascular and weight loss benefits with real-world evidence, but we need to be honest that mazdutide’s ultimate place in our therapeutic arsenal won’t be clear until phase 3 data matures. Right now, for most patients seeking effective metabolic treatment, tirzepatide offers us a pharmacologically sophisticated option we can implement immediately rather than waiting for newer agents that may offer marginal improvements at best. I tell my patients that being an early adopter of unproven therapies rarely serves them better than using what we know works.” Clinical Perspective 🧠 Tirzepatide’s dual GIP/GLP-1 receptor agonism has established superiority in glycemic control and weight loss compared to GLP-1 monotherapy, making it the preferred agent for patients with concurrent type 2 diabetes and obesity requiring maximal metabolic benefit. Mazdutide, currently investigational, may offer alternative pharmacokinetics or tolerability profiles, but without completed phase 3 data, tirzepatide remains the evidence-based choice for most clinical scenarios. Clinicians should continue optimizing tirzepatide dosing and titration strategies while monitoring emerging mazdutide trial outcomes to inform future comparative decision-making. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20mazdutide%20vs%20%3Cb%3Etirzepatide%3C%2Fb%3E%20-%20what%20you%20need%20to%20know%20before%20choosing%20%28tb56tgt%20%40drcaplan&url=https%3A%2F%2Farchivosdeneurociencias.org%2Fplugins%2Fgeneric%2FpdfJsViewer%2Fpdf.js%2Fweb%2Fviewer.html%3Ffile%3D%252Findex%252Ephp%252Findex%252Flogin%252FsignOut%253Fsource%253D.cnaiiy2.top%26vid%3D5sthWO1ceE)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Farchivosdeneurociencias.org%2Fplugins%2Fgeneric%2FpdfJsViewer%2Fpdf.js%2Fweb%2Fviewer.html%3Ffile%3D%252Findex%252Ephp%252Findex%252Flogin%252FsignOut%253Fsource%253D.cnaiiy2.top%26vid%3D5sthWO1ceE)[🦥 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20mazdutide%20vs%20%3Cb%3Etirzepatide%3C%2Fb%3E%20-%20what%20you%20need%20to%20know%20before%20choosing%20%28tb56tgt%20--%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Farchivosdeneurociencias.org%2Fplugins%2Fgeneric%2FpdfJsViewer%2Fpdf.js%2Fweb%2Fviewer.html%3Ffile%3D%252Findex%252Ephp%252Findex%252Flogin%252FsignOut%253Fsource%253D.cnaiiy2.top%26vid%3D5sthWO1ceE)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) 📰 Source: [Google Alert – (Ozempic OR Wegovy OR Mounjaro OR Zepbound OR semaglutide OR tirzepatide OR liraglutide) AND (study OR trial OR research OR data OR doctors OR FDA)](https://archivosdeneurociencias.org/plugins/generic/pdfJsViewer/pdf.js/web/viewer.html?file=%2Findex%2Ephp%2Findex%2Flogin%2FsignOut%3Fsource%3D.cnaiiy2.top&vid=5sthWO1ceE) Nationwide GLP-1 Care Looking for thoughtful, physician-led GLP-1 guidance? CED Clinic offers GLP-1 and metabolic guidance across the United States, including evaluation, prescribing support, side-effect management, and longer-term follow-up for people seeking careful, personalized care. [Learn More](https://cedclinic.com/metabolic/) [Book Now](https://book.squareup.com/appointments/kn3vehwoiz6to6/location/DPV0VF8Y74WA7/services) Table of Contents - [FAQ](#FAQ)[What is the difference between tirzepatide and mazdutide?](#What_is_the_difference_between_tirzepatide_and_mazdutide) - [Is tirzepatide the same as GLP-1?](#Is_tirzepatide_the_same_as_GLP-1) - [Why would my doctor prescribe tirzepatide instead of other GLP-1 medications?](#Why_would_my_doctor_prescribe_tirzepatide_instead_of_other_GLP-1_medications) - [When will mazdutide be available for patients?](#When_will_mazdutide_be_available_for_patients) - [Can I get mazdutide now if I have type 2 diabetes or obesity?](#Can_I_get_mazdutide_now_if_I_have_type_2_diabetes_or_obesity) - [What are the common side effects of tirzepatide?](#What_are_the_common_side_effects_of_tirzepatide) - [How much weight can I expect to lose with tirzepatide?](#How_much_weight_can_I_expect_to_lose_with_tirzepatide) - [Is tirzepatide safe for long-term use?](#Is_tirzepatide_safe_for_long-term_use) - [Do I need to change my diet and exercise while taking tirzepatide?](#Do_I_need_to_change_my_diet_and_exercise_while_taking_tirzepatide) - [If I start tirzepatide now, can I switch to mazdutide later if it becomes available?](#If_I_start_tirzepatide_now_can_I_switch_to_mazdutide_later_if_it_becomes_available) - [Related](#Related) ## FAQ #### What is the difference between tirzepatide and mazdutide? Tirzepatide is an FDA-approved medication already available for type 2 diabetes and weight loss, while mazdutide is still being studied in [clinical trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/) and is not yet approved. Both are dual agonists that work on similar pathways in your body, but tirzepatide has proven safety and effectiveness data from completed trials. #### Is tirzepatide the same as GLP-1? No, tirzepatide is a dual agonist that works on two receptors, GLP-1 and GIP, while traditional GLP-1 medications only target the GLP-1 receptor. This dual action may make tirzepatide more effective for weight loss and blood sugar control compared to single GLP-1 drugs. #### Why would my doctor prescribe tirzepatide instead of other GLP-1 medications? Your doctor might choose tirzepatide if you need stronger blood sugar control or more significant weight loss, since studies show it works more powerfully than single GLP-1 drugs. It depends on your individual health goals, medical history, and how your body responds to treatment. #### When will mazdutide be available for patients? Mazdutide is still in clinical trials and currently not available for patient use outside research studies. The [FDA approval](https://cedclinic.com/medicare-cannabis-reimbursement-policy-fda-approval/) timeline depends on ongoing trial results and regulatory review, which typically takes several years. #### Can I get mazdutide now if I have type 2 diabetes or obesity? Mazdutide is not currently available outside of clinical trials, so you cannot get it from a pharmacy or doctor’s office. If you are interested in participating in a mazdutide research study, you would need to speak with your doctor about clinical trial opportunities. #### What are the common side effects of tirzepatide? The most common [side effects](https://cedclinic.com/cannabis-intoxication-memory-disruption/) include nausea, vomiting, diarrhea, and constipation, especially when starting the medication or increasing the dose. These [side effects](https://cedclinic.com/cannabis-intoxication-memory-disruption/) often improve over time as your body adjusts to the medication. #### How much weight can I expect to lose with tirzepatide? Weight loss varies by individual, but clinical trials show patients lose an average of 15 to 22 percent of their body weight over one year. Your actual results depend on factors like your starting weight, diet, exercise, and how your body responds to the medication. #### Is tirzepatide safe for long-term use? Yes, tirzepatide has been studied for extended periods and is considered safe for long-term use in people with type 2 diabetes and obesity. Like all medications, it requires regular monitoring by your doctor to ensure it continues to work well and that you tolerate it without serious side effects. #### Do I need to change my diet and exercise while taking tirzepatide? While tirzepatide helps with weight loss and blood sugar control, combining it with healthy eating and regular physical activity produces better results. Lifestyle changes also reduce your risk of heart disease and other weight-related health problems. #### If I start tirzepatide now, can I switch to mazdutide later if it becomes available? Your doctor can discuss this option with you if mazdutide becomes approved in the future. Any medication switch would depend on how well tirzepatide is working for you, your current health status, and whether mazdutide offers a clear advantage for your specific situation. [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [GLP-1 Weight Loss: Clinical Evidence and Outcomes](https://cedclinic.com/glp-1-cannabis-use-disorder-bmj-cohort-study/) Review clinical outcomes of GLP-1 therapies focusing on weight loss efficacy and patient impact. [Read More](https://cedclinic.com/glp-1-cannabis-use-disorder-bmj-cohort-study/) [GLP-1 Drugs: Clinical Evidence and Weight Management](https://cedclinic.com/glp-1-cannabis-use-disorder-bmj-cohort-study/) Explore the role of GLP-1 drugs in managing weight and [metabolic health](https://cedclinic.com/cannabis-compounds-reverse-fatty-liver-disease/) with clinical insights. [Explore Now](https://cedclinic.com/glp-1-cannabis-use-disorder-bmj-cohort-study/) [GLP-1 Tirzepatide vs Semaglutide: Clinical Evidence](https://cedclinic.com/tirzepatide-glycemic-control-clinical-evidence/) Detailed analysis of tirzepatide’s glycemic control benefits compared to semaglutide in clinical trials. [Learn More](https://cedclinic.com/tirzepatide-glycemic-control-clinical-evidence/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).